Aug 20 — Yingxi Intelligence said it has signed a formal R&D collaboration with Byterna Therapeutics to build a next‑generation, AI‑native mRNA R&D engine. The partnership will focus on AI neoantigen prediction and sequence design, circular mRNA, tar

2026-08-20

Aug 20 — Yingxi Intelligence said it has signed a formal R&D collaboration with Byterna Therapeutics to build a next‑generation, AI‑native mRNA R&D engine. The partnership will focus on AI neoantigen prediction and sequence design, circular mRNA, targeted delivery, automated experimentation and smart manufacturing to develop personalized cancer vaccines and related therapies.